HomeBNTX • NASDAQ
add
BioNTech SE - ADR
Previous close
$90.54
Day range
$91.18 - $95.14
Year range
$79.52 - $123.98
Market cap
25.02B USD
Avg Volume
1.29M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 907.40M | -23.75% |
Operating expense | 907.20M | 15.13% |
Net income | -305.00M | -217.53% |
Net profit margin | -33.61 | -254.10% |
Earnings per share | -0.33 | -130.56% |
EBITDA | -266.95M | -195.92% |
Effective tax rate | -34.12% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 13.74B | -13.28% |
Total assets | 21.99B | -2.40% |
Total liabilities | 2.76B | -11.36% |
Total equity | 19.22B | — |
Shares outstanding | 239.97M | — |
Price to book | 1.18 | — |
Return on assets | -3.49% | — |
Return on capital | -3.96% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -305.00M | -217.53% |
Cash from operations | 309.50M | 166.80% |
Cash from investing | -2.73B | -549.25% |
Cash from financing | -14.30M | -95.89% |
Net change in cash | -2.42B | -1,860.74% |
Free cash flow | -1.44B | -27.63% |
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
7,807
